Center for Blood Disorders
The Center for Blood Disorders provides comprehensive care services for the treatment
of bleeding and clotting disorders and sickle cell disease.
Our physicians, nurses and social workers are available to provide personalized care
for those with:
- sickle cell disease
- hemophilia
- von Willebrand disease
- thrombophilia
We are affiliated with the Medical College of Georgia at Augusta University.
Learn More About Our Services
Hemophilia Treatment Center
Thrombophilia Care Program
Our Mission
Our goal is to improve quality of life for people with blood disorders through comprehensive
care, addressing the physical, emotional, spiritual, and social needs of our patients
and their families.
Research
Research is a vital part of the Center for Blood Disorders. Our dedicated team is
designed to provide leading clinical and translational research in nonmalignant blood
disorders. For over 20 years, Dr. Kutlar has conducted groundbreaking research aimed
to improve treatment and care for sickle cell disease.
In the News
Dec. 25, 2017Augusta Chronicle
Alexis Jones-Heggs, was the first in the Augusta area to receive a bone-marrow transplant
to try and cure her of sickle cell disease as part of a national clinical trial that
involves the Sickle Cell Center at Augusta University.
Continue Reading
|
Oct. 30, 2017JagWire
The Medical College of Georgia and Augusta University Health have joined the first
large national clinical trial to determine if bone marrow transplantation should be
part of the standard of care for patients with sickle cell disease.
Continue Reading
|
Sickle Cell Disease Studies
The Role of Endothelin-1 in Sickle Cell Disease
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab),
with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive
Crisis
A Phase 3 Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440
Administered Orally to Patients with Sickle Cell Disease
A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and
Young Adults with Severe Sickle Cell Disease (BMT CTN 1503) (STRIDE 2)
Principal Investigator: Jeremy Pantin, MD
Contact: Latanya Bowman, RN, BSN 706-721-2171 or Gita Giddens RN, BSN, OCN 706-721-1374
Sickle Cell Disease Implementation Consortium (SCDIC) Registry
Research activities are mostly sponsored by the National Institutes of Health and
pharmaceutical companies.